ProShare Advisors LLC Has $153.76 Million Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

ProShare Advisors LLC lessened its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 6.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 466,806 shares of the medical instruments supplier’s stock after selling 33,856 shares during the period. ProShare Advisors LLC owned about 0.64% of West Pharmaceutical Services worth $153,761,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in WST. Fidelis Capital Partners LLC acquired a new position in West Pharmaceutical Services during the 1st quarter worth approximately $27,000. Crewe Advisors LLC grew its stake in shares of West Pharmaceutical Services by 322.7% during the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock worth $31,000 after buying an additional 71 shares during the last quarter. Quarry LP increased its holdings in shares of West Pharmaceutical Services by 155.3% during the fourth quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock worth $34,000 after buying an additional 59 shares in the last quarter. Hazlett Burt & Watson Inc. bought a new position in shares of West Pharmaceutical Services in the 1st quarter valued at $40,000. Finally, Northwest Investment Counselors LLC bought a new position in shares of West Pharmaceutical Services in the 1st quarter valued at $40,000. Institutional investors own 93.90% of the company’s stock.

West Pharmaceutical Services Trading Down 1.0 %

NYSE WST opened at $308.15 on Friday. The company has a market cap of $22.45 billion, a price-to-earnings ratio of 40.65, a price-to-earnings-growth ratio of 10.58 and a beta of 1.01. West Pharmaceutical Services, Inc. has a twelve month low of $265.00 and a twelve month high of $413.70. The company has a quick ratio of 1.68, a current ratio of 2.34 and a debt-to-equity ratio of 0.03. The business’s fifty day moving average is $303.37 and its 200 day moving average is $337.31.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.22). The firm had revenue of $702.10 million for the quarter, compared to analyst estimates of $729.36 million. West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The business’s revenue for the quarter was down 6.9% compared to the same quarter last year. During the same period in the previous year, the business posted $2.11 earnings per share. As a group, sell-side analysts expect that West Pharmaceutical Services, Inc. will post 6.42 EPS for the current fiscal year.

Insider Buying and Selling at West Pharmaceutical Services

In other news, VP Charles Witherspoon sold 1,029 shares of West Pharmaceutical Services stock in a transaction on Monday, August 19th. The shares were sold at an average price of $300.00, for a total transaction of $308,700.00. Following the transaction, the vice president now owns 1,478 shares in the company, valued at $443,400. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.